TITLE

Bioidentical Hormone Therapy

AUTHOR(S)
Files, Julia A.; Ko, Marcia G.; Pruthi, Sandhya
PUB. DATE
July 2011
SOURCE
Mayo Clinic Proceedings;Jul2011, Vol. 86 Issue 7, p673
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The change in hormonal milieu associated with perimenopause and menopause can lead to a variety of symptoms that can affect a woman's quality of life. Postmenopausal hormone therapy (HT) is an effective, well-tolerated treatment for these symptoms. However, combined HT consisting of conjugated equine estrogen and medroxyprogesterone acetate has been associated with an increased number of health risks when compared with conjugated equine estrogen alone or placebo. As a result, some women are turning to alternative hormonal formulations known as compounded bioldentical HT because they perceive them to be a safer alternative. This article defines compounded bioidentical HT and explores the similarities and differences between it and US Food and Drug Administration-approved HT. We will examine the major claims made by proponents of compounded bioidentical HT and recommend strategies for management of patients who request bioidentical HT from physicians.
ACCESSION #
62807425

 

Related Articles

  • Paroxetine Capsules (Brisdelleâ„¢). Elliott, William T.; Chan, James // Internal Medicine Alert;7/29/2013, Vol. 35 Issue 14, p110 

    The article focuses on a study that was conducted to examine the efficacy and safety of paroxetine for the treatment of vasomotor symptoms in postmenopausal women.

  • An Innovative, Reusable Menstrual Cup that Enhances the Quality of Women's Lives during Menstruation. Shihata, Alfred; Brody, Steven // British Journal of Medicine & Medical Research;7/1/2014, Vol. 4 Issue 19, p3581 

    Objective: A) To evaluate the acceptability of a unique, Cost-effective, reusable, and environmentally safe device for menstrual blood collection among culturally diverse women. B) To enhance the quality of life for women during menstruation. Methods: The first author developed a unique,...

  • Women nuturing others forget to nurture selves. Van Buren, Abigail // Adirondack Daily Enterprise;5/10/2010, Vol. 117 Issue 110, p6 

    The article focuses on the effort of the Food and Drug Administration Office of Women's Health and the Federal Citizen Information Center to help women take care of themselves in the U.S.

  • FDA Committee Supports Depo. Klitsch, Michael // Family Planning Perspectives;Jul/Aug92, Vol. 24 Issue 4, p146 

    This article reports on the approval given by the U.S. Food and Drug Administration's (FDA) Fertility and Maternal Health Drugs Advisory Committee regarding the use of an injectable hormonal contraceptive in the U.S. on June 19, 1992. One injection of the drug, depot medroxyprogesterone acetate...

  • The best treatment is sometimes none at all. DePaolis, Michael D. // Primary Care Optometry News;Sep2008, Vol. 13 Issue 9, p3 

    The author asserts the need for optometrists to consider quality of life before proceeding with therapeutics or surgery. He cites the implementation of quality of life metrics for assessing the efficacy of certain new drugs and devices by the U.S. Food and Drug Administration (FDA). He describes...

  • Passion, interrupted. Yoffe, Emily // Health (Time Inc. Health);May2005, Vol. 19 Issue 4, p66 

    Presents an article about the use of testosterone cream to increase sexual drive. Rejection of the approval of Intrinsa testosterone patch product by the U.S. Food and Drug Administration; Testosterone level in premenopausal women; Ineffectiveness of the cream. INSET: Is testosterone for you?.

  • FDA committee backs approval for "female Viagra". Roehr, Bob // BMJ: British Medical Journal;6/13/2015, Vol. 350 Issue 8012, ph3097 

    The article reports on the approval given by the U.S. Food and Drug Administration to the drug flibanserin for the treatment of premenopausal women with hypoactive sexual design from pharmaceutical company Sprout Pharmaceuticals.

  • PREGNANT WOMEN AND TUNA.  // Electronic Ardell Wellness Report (E-AWR);8/2/2002, p1 

    Discusses the harmful effect of the presence of tuna in the diet of pregnant women according to a study conducted by the U.S. Food and Drug Administration (FDA) and government scientists. Possibility of damage to an unborn baby's developing brain from high mercury level found in tuna;...

  • Office of women's health. Stehlin, Isadora B. // FDA Consumer;Oct96, Vol. 30 Issue 8, p25 

    Features the Food and Drug Administration's (FDA) Office of Women's Health. Funding for microbiologist Mary Lou Tortorello's proposed project for developing a rapid test for Listeria monocytogenes; Annual budget; Partnerships with other government agencies and advocacy groups to advance women's...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics